None
Quote | Prescient Therapeutics Ltd (OTCMKTS:PSTTF)
Last: | $0.145 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.145 |
High: | $0 |
Low: | $0 |
Volume: | 100,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Prescient Therapeutics Ltd (OTCMKTS:PSTTF)
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting. The team briefed an exp...
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL). The designation from the Office of Orphan Product...
Message Board Posts | Prescient Therapeutics Ltd (OTCMKTS:PSTTF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Prescient Therapeutics Ltd Company Name:
PSTTF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of Cell and Gene Therapy (ISCT)’s annual meeting. The team briefed an exp...
(NewsDirect) Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL). The designation from the Office of Orphan Product...